Pfizer’s prostate cancer combo moves to earlier line on expanded US approval - Pharmaceutical Technology

The FDA expands Talzenna-Xtandi's label as the cancer treatment paradigm shifts towards the use of mutation-specific targeted therapies. Talzenna-Xtandi secures an FDA label expansion as the cancer treatment paradigm shifts towards the use of mutation-specific targeted therapies. The FDA label expansion of Talzenna-Xtandi brings the combination therapy into an earlier line within the prostate cancer treatment paradigm. Credit: Jo Panuwat D / Shutterstock.com. The US Food and Drug Administration (FDA) has awarded a label expansion to Pfizer’s targeted oncology combination of Talzenna (talazoparib) and Xtandi (enzalutamide) – expanding its reach to earlier lines of treatment for prostate cancer patients. Following…

Source: Pharmaceutical Technology